Pharmadrug Inc. (PHRX.CN) Research

Pharmadrug Inc., a Toronto-based specialty pharmaceutical firm, is dedicated to the research, development, and market introduction of controlled substances and natural therapeutics, such as psychedelics, cannabis, and other approved compounds derived from nature. The company also manages the import and supply of medical cannabis to pharmacies across Germany and the broader European Union. Additionally, it operates Super Smart, an entity focused on advancing the application of functional and psilocybin mushrooms, and engages in studies to reformulate established natural medicines. Pharmadrug maintains key research collaborations, including an agreement with the University of Michigan to explore the potential role of N, N-dimethyltryptamine (DMT) in various states of consciousness. It has also partnered with the Southwest Research Institute for the manufacturing of cepharanthine and entered into a clinical trial agreement with Johns Hopkins University to compare the acute and enduring psychological and neural effects of DMT against another potent active molecule. The company adopted its current name in October 2019, having previously operated as Aura Health Inc.

Open Pharmadrug Inc. (PHRX.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.